Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma

Bookmark and Share
Published: 4 Jun 2021
Views: 186
Rating:
Save
Dr Terence Friedlander - UCSF, San Francisco, USA

Dr Terence Friedlander talks to ecancer about the updates in the EV-103 study focusing on durability results of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma.

He begins by talking about the intentions of combining enfortumab vedotin with pembrolizumab, both already FDA approved, stating that enfortumab vedotin by itself may induce an immunogenic cell death, so adding pembrolizumab is thought to increase the immune response.

Dr Friedlander then goes on to explain that the study accrued 45 patients who were dosed on a three week cycle. What was found when patients were treated with the combination was that 73.3% had at least a clear partial response to therapy, which is very high compared to other regimens that are approved for this patient population.

He concludes by explaining that the data presented here is only 2 cohorts of a much bigger study. Currently there is an ongoing randomised cohort that compares enfortumab vedotin alone vs enfortumab vedotin + pembrolizumab, which will give a better sense of what the true activity of each drug is by itself as well as being a combination.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.